JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

Search

Fate Therapeutics Inc

Closed

SectorHealthcare

1.16 -10.77

Overview

Share price change

24h

Current

Min

1.16

Max

1.31

Key metrics

By Trading Economics

Income

15M

-38M

Sales

-231K

1.6M

Profit margin

-2,309.454

Employees

181

EBITDA

4.3M

-38M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+286.92% upside

Dividends

By Dow Jones

Next Earnings

11 sie 2025

Market Stats

By TradingEconomics

Market Cap

9.2M

132M

Previous open

11.93

Previous close

1.16

News Sentiment

By Acuity

48%

52%

153 / 375 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 lip 2025, 23:57 UTC

Acquisitions, Mergers, Takeovers

EQT: To Spend Y407.82B for Tender Offer

29 lip 2025, 23:56 UTC

Acquisitions, Mergers, Takeovers

EQT: Tender Offer Price Is Y5,700 a Share

29 lip 2025, 23:54 UTC

Acquisitions, Mergers, Takeovers

EQT To Start Tender Offer for Fujitec

29 lip 2025, 23:50 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 lip 2025, 23:36 UTC

Market Talk

Gold Steady Ahead of FOMC Decision -- Market Talk

29 lip 2025, 22:57 UTC

Market Talk

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 lip 2025, 22:50 UTC

Market Talk

Mondelez Warns of Price Increases in North America -- Market Talk

29 lip 2025, 22:44 UTC

Acquisitions, Mergers, Takeovers

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 lip 2025, 22:41 UTC

Acquisitions, Mergers, Takeovers

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 lip 2025, 22:41 UTC

Acquisitions, Mergers, Takeovers

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 lip 2025, 22:35 UTC

Earnings

IGO Maintains Nova Life of Mine Production Guidance

29 lip 2025, 22:35 UTC

Earnings

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 lip 2025, 22:35 UTC

Earnings

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 lip 2025, 22:34 UTC

Earnings

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 lip 2025, 22:34 UTC

Earnings

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 lip 2025, 22:34 UTC

Market Talk
Earnings

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 lip 2025, 22:33 UTC

Earnings

IGO Had A$279.7 Million of Cash at End-June

29 lip 2025, 22:33 UTC

Earnings

IGO 4Q Underlying Free Cash A$2.4 Million

29 lip 2025, 22:33 UTC

Earnings

IGO FY Sales Revenue A$512.5 Million

29 lip 2025, 22:33 UTC

Earnings

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 lip 2025, 22:32 UTC

Earnings

IGO FY Nickel Production 17,173 Tons

29 lip 2025, 22:32 UTC

Earnings

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 lip 2025, 22:32 UTC

Earnings

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 lip 2025, 22:31 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

29 lip 2025, 22:31 UTC

Market Talk
Earnings

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 lip 2025, 22:31 UTC

Earnings

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 lip 2025, 22:31 UTC

Earnings

IGO FY Spodumene Production 1.48 Million Tons

29 lip 2025, 22:30 UTC

Earnings

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 lip 2025, 22:30 UTC

Earnings

IGO 4Q Underlying Ebitda A$62 Million

29 lip 2025, 22:22 UTC

Earnings

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

286.92% upside

12 Months Forecast

Average 5.03 USD  286.92%

High 12 USD

Low 2 USD

Based on 11 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

3

Buy

8

Hold

0

Sell

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

153 / 375 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.